Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib and anti-PD-1 antibody as adjuvant therapy for HCC
NCT04418401Phase 1Completed
- Sponsor
- Zhejiang University
- Start
- Jun 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Zhejiang University. Started Jun 2020; status: completed.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04418401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418401.